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ABSTRACT
The costs of a hospital-wide selective screening programme were analysed for a period of 19 months.
During this time, 539 inpatients were screened, of whom 111 were MRSA-positive. Based on
microbiological costs (staff and materials) and the costs of preventive contact isolation for 2 days until
microbiological results were available (including material costs for medical consumable goods and the
costs of additional nursing time), a total of €26 241.51 was spent for the 539 patients screened. Based on
cost units, the costs were €39.96 for a patient found to be MRSA-negative and €82.33 for a patient found
to be MRSA-positive. Under the prospective diagnosis related groups (DRG) payment system in
Germany, the costs of a prolonged hospital stay resulting from a hospital-acquired MRSA infection
(HA-MRSA-I) are not reimbursed adequately by revenues, with a calculated average cost-revenue
loss ⁄patient with HA-MRSA-I of €5705.75. The screening programme was able to prevent 48% of
predicted HA-MRSA-Is (35.2 patients with infection), thereby saving a predicted €200 782.73. After
subtracting the screening costs, there was a net saving of €110 236.56 annually. A sensitivity analysis of
the break-even points for different screening frequencies and different MRSA incidence rates indicated
that the screening programme became cost-effective at a low MRSA incidence rate, meaning that it can
be recommended for most hospitals with an MRSA problem.
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INTRODUCTION
In common with the general European trend, the
incidence of methicillin-resistant Staphylococcus
aureus (MRSA) in Germany has increased dra-
matically during the last few years [1,2]. How-
ever, despite a high incidence of MRSA, the battle
against the spread of this multiresistant organism
in the hospital setting need not necessarily be lost,
provided that appropriate infection control pro-
grammes are implemented. Thus, in Denmark,
there was an increase in the incidence of MRSA,
which then decreased after the implementation of
screening and antibiotic use policies [3].
Screening of potential MRSA carriers at hospital
admission has proven to be effective in reducing
hospital-acquiredMRSA infections (HA-MRSA-Is)
[4–6], but the introduction of screening measures
in the hospital setting may be inhibited by the
associated investment and operational costs.
However, hospital-acquired infections are associ-
ated with an increased length of hospital stay and
with increased hospital costs [7–12], and this
becomes more important with a prospective
payment system. Previously, there was no ﬁnan-
cial incentive in Germany to implement infection
control programmes, as the costs for treating
hospital-acquired infections were compensated
through revenues for the increased length of
hospital stay. Since the beginning of 2004, there
has been a rearrangement of the hospital payment
system. The new payment system is based on
case-based lump sums according to diagnosis
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related groups (DRGs). To maximise a hospital’s
cost-effectiveness, it is essential to minimise the
patient’s length of hospital stay, and therefore to
minimise the number of hospital-acquired infec-
tions. Thus, the cost of performing screening
should be compared with the potential cost
resulting from HA-MRSA-Is.
There have been two cost-analysis studies of
the consequences of screening potential MRSA
carriers at hospital admission [12,13], which both
showed that the costs of treating HA-MRSA-Is in
the absence of screening were much higher than
the costs involved in implementing a screening
programme. The signiﬁcance of these studies is
limited, since they were based only on mathe-
matical models of reduced transmission and the
associated reduced frequency of hospital-
acquired infections. Thus, there was no evidence
that screening was able to prevent HA-MRSA-Is.
The aim of the present study was to calculate the
costs for a selective screening programme of
potential MRSA carriers at hospital admission,
the cost-revenue difference for patients with
HA-MRSA-I in the context of the DRG payment
system, and to compare the screening costs and
the costs saved as a result of preventing
HA-MRSA-Is by the screening programme, based
on observed empirical data.
METHODS AND MATERIALS
The cost analysis was based on a hospital-wide selective
screening programme described in detail separately [6]. The
cost analysis used the same population as the cohort study
which demonstrated that screening is able to prevent
HA-MRSA-Is [6].
Calculation of costs for screening patients
Total screening costs were calculated for the 19-month screen-
ing period, during which 539 patients were screened, of whom
111 were MRSA-positive [6]. The costs were calculated for
prophylactic contact isolation for 2 days between hospital
admission and the results of the microbiological tests.
Most of the 539 patients screened were treated initially in a
general unit for admission before they were transferred to
specialist departments (surgical, medical, intensive care unit
(ICU) or others). During the 19-month period from April 2001
to November 2002, the usage and costs of medical consum-
ables required to perform contact isolation in the general unit
were monitored, followed by calculation of the mean usage
and the associated mean costs. These were multiplied by 539 to
obtain the total costs of screening.
Use of gowns, gloves,masks, disinfectant for hands, and hair
caps was monitored. To reduce the time required for decolo-
nisation measures if patients were MRSA-positive, all patients
screened were washed routinely at the beginning of their
hospital stay and then daily with c.2 mL of antiseptic soap. The
material costs for washing were added to the costs for isolation
measures.
Also monitored was the frequency, according to the
microbiology laboratory records, at which swabs were taken
from locations other than the nose or throat (which depended
on each patient’s risk factors). The mean cost for all samples
collected from one patient was calculated, and then stratiﬁed
for patients who were MRSA-negative and patients who were
MRSA-positive. In addition to the material costs for specimens,
the laboratory material and personnel costs were also calcu-
lated, based on the laboratory methods used during the
screening programme [6]. These were monitored for a period
of 2 months.
The mean frequency of entry into the contact isolation room
in this setting was 18.6 ⁄patient (9.3 entries ⁄day). It was
estimated that an additional 3 min was needed to enter and
leave the contact isolation room. Therefore, for each patient
screened, the costs for 1 h of additional nursing time to
perform the screening measures (30 min ⁄day) were included
in the calculation, in accordance with the methods and results
of other studies [5,12,13]. In this estimate, the costs for
collecting specimens and for decolonisation measures were
included in the calculation. For patients who were MRSA-
positive, the costs for cleaning the room by trained personnel
were also included.
There was never any need to deny hospital admission to a
patient (there was an average bed utilisation rate of 79.2%), so
no provision was made for possible revenue losses when twin
roomswere used as single rooms for contact isolation purposes.
Calculation of costs for patients with HA-MRSA-I
In the cohort study described separately [6], 48 patients with
HA-MRSA-I were detected in the control cohort, compared
with 38 patients with HA-MRSA-I in the screening cohort. The
average costs were calculated for the total of 86 patients.
As a ﬁrst step, the DRGs for the 86 patients were
determined by coding their diagnoses (ICD-10) and surgical
procedures (OPS-301) where appropriate. These codes,
together with data regarding age, sex, duration of any
mechanical ventilation, and length of hospital stay were
processed using DRG grouper computer software (KODIP).
DRG revenues for a patient are based on epidemiological data
regarding their length of hospital stay (LOS). For each DRG
there is a threshold value of the LOS (97.5 percentile of the LOS
of all patients with the same DRG). This threshold value was
determined by the German DRG Institute (InEK GmbH), based
on a Germany-wide DRG pretest. If the patient does not
exceed this threshold value, hospital costs are compensated for
by DRG case-based lump sums. If patients exceed this
threshold value, the hospital is reimbursed the daily surchar-
ges, which are much lower than the mean revenues ⁄day when
the patient does not exceed the threshold value. For each
patient exceeding the threshold value, the difference between
the LOS and the threshold value was calculated, as well as the
hospital revenues in terms of surcharges. The difference
between surcharge revenues and the costs for the prolonged
hospital stay was then calculated. For this purpose, the
revenues ⁄day before the introduction of the DRG payment
system were used as surrogate parameters for the hospital
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costs. These daily costs depended on the hospital department
where the patients were treated for HA-MRSA-I, and ranged
from €266.03 for a stay in a vascular surgery department to
€1299.05 for a stay in an ICU.
Comparison of screening costs and costs for prevented
HA-MRSA-Is
The mean cost-revenue difference for a single patient with
HA-MRSA-I was multiplied by the number of 35.2 cases of
HA-MRSA-I that were calculated as having been prevented by
the screening programme during the 19-month period [6].
These costs were compared with the total costs required to
screen the 539 patients. This comparison was based on an
incidence rate of MRSA-positive screened patients (as a
percentage of all inpatients) of 0.3% (111 MRSA-positive
screened patients among 36 962 inpatients) and a screening
frequency of 1.5% of all admissions. A sensitivity analysis was
then used to calculate the incidence rate at which the selective
screening programme became cost-effective in this setting with
different screening frequencies. For this purpose, it was
assumed that the absolute frequency of positive MRSA
screened patients remained constant above the screening
frequency of 1.5%, since the MRSA prevalence in a population
is constant and cannot be affected by the screening pro-
gramme. Thus, with a higher screening frequency, only the
absolute frequency of screened patients found to be MRSA-
negative increases. It was also assumed that the detection of
3.15 MRSA-positive screened patients prevented one hospital-
acquired MRSA infection (111 MRSA-positive screened pa-
tients divided by the predicted 35.2 prevented HA-MRSA-Is)
and saved the associated costs. All calculations were based on
costs incurred by the hospital in 2002.
RESULTS
Costs for screening patients
For 539 patients, the screening expenditure
amounted to €26 241.51 for the 19-month screen-
ing period (€16 573.58 ⁄ year). These costs com-
prised €15 407.71 for medical consumables and
€10 833.90 for additional nursing time. Thus
€236.41 was expended in order to detect one
positive MRSA patient at hospital admission
(€26 241.51 divided by 111 MRSA-positive
screened patients). The screening costs (i.e., for
contact isolation precautions and laboratory
costs) were €39.96 for a patient who was
MRSA-negative, and €82.33 for a patient who
was MRSA-positive (Table 1). The difference in
screening costs for MRSA-positive and MRSA-
negative screened patients was caused by the
higher laboratory costs for MRSA-positive
patients and the costs of room cleaning by
trained personnel.
All patients who were MRSA-positive had
more specimens taken (in addition to those from
nose and throat), with an average of 4.35 addi-
tional specimens ⁄patient (range 1–13 specimens).
Swabs, additional to those from nose and throat,
were collected from 340 (79.5%) of the 428 MRSA-
negative patients, with an average of 2.18 speci-
mens ⁄patient (range 1–13). Most of the additional
specimens were collected from wounds (pressure
sores) and invasive devices.
Costs for hospital-acquired infections
Of 86 patients with HA-MRSA-I, 61 (70.9%)
exceeded the corresponding DRG threshold value
for the LOS, and were included in further cost-
revenue analysis. There was no difference in age
(mean 77.0 vs. 73.5 years; two tailed t-test,
p 0.191), in the corresponding DRG threshold
value (26.0 vs. 24.7 days; p 0.347), or in the
frequency of co-morbidities (mean 3.6 vs.
3.8 ⁄patient; p 0.807) between the patients who
exceeded the threshold value and those who did
not. The 61 patients remained in hospital for an
average of 18.1 days in excess of the threshold
value. The excess was highest for hospital-
acquired pneumonia or post-operative wound
infection, and lowest for hospital-acquired MRSA
urinary tract infection (Table 2).
The average revenue ⁄patient in terms of
surcharges resulting from an overstay was
€2907.58 ⁄patient, or €160.64 ⁄day of overstay. In
contrast, the average costs for hospital stay were
€10 951.76 ⁄patient, or €604.48 ⁄day, giving a dif-
ference between hospital costs and revenues of
€8044.18 ⁄patient. Thus, only 26.55% of the hospi-
tal costs for patients who exceeded the DRG
threshold value as a result of HA-MRSA-I were
compensated by revenues. This difference was
Table 1. Average costs for screening patients during
2 days of preventive contact isolation
Screened patients
found to be
MRSA-negative (€)
Screened patients
found to be
MRSA-positive (€)
Masks (one for €0.089) 1.66 1.66
Gloves (one for €0.045) 1.67 1.67
Gowns (one for €0.62 €) 3.66 3.66
Hair caps (one for €0.11) 1.20 1.20
Disinfectant (1 L for €3.60) 0.27 (74.4 mL) 0.27 (74.4 mL)
Additional nursing time
(1 h for €20.10)
20.10 20.10
Washing with antiseptic soap
(500 mL for € 2.89)
0.023 0.023
Laboratory costs
(materials and personnel)
11.38 44.25
Costs for room cleaning – 9.50
Total 39.96 82.33
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highest for hospital-acquired MRSA pneumonia
(Table 2), resulting from the costs of a prolonged
stay in an ICU.
Based on the 70.9% of screened patients who
exceeded the DRG threshold value, thereby caus-
ing mean net costs of €10 951.76 ⁄patient and a
mean cost-revenue loss of €8044.18, together with
the 29.1% of screened patients who did not
exceed the DRG threshold value, the mean
cost ⁄patient with HA-MRSA-I was €7768.10, and
the mean costs-revenue loss was €5705.75.
Comparison of screening costs and costs for
HA-MRSA-I
The screening programme [6] was estimated to
have prevented 35.2 cases of HA-MRSA-I, thereby
saving 35.2 · €5705.75, which amounts to
€200 782.73. After subtracting the total costs for
the patient screening (€26 241.51), there was a
predicted net cost-saving of €174 541.22 during
the 19-month period (€110 236.56 annually). The
screening programme became cost-effective at
the point where a mere 2.9 cases of HA-MRSA-I
were prevented ⁄ year (€16 573.58 divided by
€5705.75). The sensitivity analysis indicated that
screening became cost-effective in this context if
>0.03% of all inpatients were MRSA-positive at
hospital admission, and was still cost-effective if
<13.7% of all inpatients met the screening criteria.
The break-even points for screening frequencies
of >1.5% of all inpatients (as used in this context)
and other incidence rates of MRSA-positive
screened patients are shown in Fig. 1. The net
cost-saving of a screening programme rises with
a growing incidence rate of MRSA-positive
Table 2. Average length of over-
stay, revenues and costs of patients
with hospital-acquired MRSA infec-
tion (n = 61) that exceeded the
threshold value of the correspond-
ing diagnosis related group (DRG)
Average
length of
overstay (days)a
Average
revenues ⁄
patient (€)
Average
costs ⁄
patient (€)
Difference
between revenues
and costs (€)
Post-operative wound infection (n = 21) 28.85 6944.32 11 354.59 )4410.27
Pneumonia (n = 9) 28.55 6792.49 29 277.25 )22 484.76
Bloodstream infection (n = 15) 21.93 5013.93 13 536.52 )8522.59
Urinary tract infection (n = 5) 14.00 2894.36 4656.82 )1762.46
Other types of infection (n = 11) 24.55 4317.86 5299.12 )981.26
aDifference between length of stay of the patient and the threshold value of the corresponding DRG according to
which the revenues are generated only in terms of surcharges.
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Fig. 1. Sensitivity analysis for the incidence rate of MRSA carriage at hospital admission. The screening programme
becomes cost-effective at the intercept points (break-even points) between the black straight line and the dashed straight
lines. If a hospital decides not to operate a screening programme, the costs indicated by the black straight line correspond
to the costs required to treat the hospital-acquired MRSA infections that may otherwise have been prevented. The costs for
the different screening frequencies apply to a hospital setting with 700 beds and c.23 000 inpatients annually.
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screened patients and a decreasing screening
frequency (Fig. 1). Conversely, to perform an
aggressive screening strategy with a high screen-
ing frequency, there must be a high MRSA
prevalence for the programme to be cost-effective.
If there is a low MRSA prevalence, the screening
does not prevent a sufﬁcient number of cases of
HA-MRSA-I to cover the costs of the screening
programme. Screening of all incoming patients
would become cost-effective if at least 22% of
patients screened were MRSA-positive (Fig. 1). If
a hospital decides not to perform a screening
programme, then the annual sum of costs that
would be saved by the screening programme
(diagonal straight line in Fig. 1) corresponds to the
costs required to treat the cases of HA-MRSA-I
that would otherwise have been prevented.
DISCUSSION
Hospital-acquired infections are associated with
an increased length of hospital stay and
increased costs [7–12]. The highest costs are
incurred by patients with hospital-acquired
bloodstream infections and by patients with
HA-MRSA-I [7,8]. Kim et al. [9] calculated that
the additional costs for a case of HA-MRSA-I
were 14 360 Canadian Dollars (€9141), while the
additional costs for MRSA infections acquired in
an ICU were found to be US $9275 (€7215) ⁄
patient compared with uninfected controls [12].
Compared with infections caused by methicillin-
sensitive S. aureus, Abramson et al. [10] calcula-
ted additional costs of US $9794 (€7618) for
hospital-acquired bloodstream infections, while
Engemann et al. [11] calculated additional costs
of US $13 901 (€10 813) for post-surgical wound
infections.
Although there is a large variation in these
costs because of different study designs, settings,
populations and year of publication, the overall
costs for HA-MRSA-Is are of the same magnitude
as that calculated in the present study. However,
these costs are only interesting from a broader
macroeconomic perspective, and not for individ-
ual hospital managers, as long as the costs for
hospital-acquired infections are compensated for
by the revenues received for the prolonged
hospital stay. Under the new prospective DRG
payment system, these costs also become import-
ant for hospital managers, as these costs are not
compensated for by the revenues received.
The ﬁnding that costs for hospital-acquired
infections are not reimbursed adequately is not
new [8,14,15]. Haley et al. [15] found that 37% of
the DRGs for patients with hospital-acquired
infections cannot be affected by co-morbidities
and complications (e.g., HA-MRSA-Is), and hence
the total hospital costs for these cases were not
reimbursed. Even if patients were shifted into a
higher DRG by complications such as hospital-
acquired infections, the average payment increase
was only $448 (€348) ⁄ infection [15]. It is important
to stress that, under the DRG payment system, the
hospital faced a total cost-revenue loss of
€5705.75 ⁄patient with HA-MRSA-I. MRSA also
contributes to the total frequency of all S. aureus
infections [13,16,17], and therefore increases costs
by raising the absolute number of patients who
have to be treated because of their infection.
When the increased mortality (non-monetary
costs) associated with patients with hospital-
acquired MRSA bloodstream infections [18,19] is
taken into account, it is clearly important to focus
infection control measures on HA-MRSA-Is.
The present study had the limitation that it did
not use a real cost calculation for the HA-MRSA-
Is (in Germany, unit cost accounting for hospitals
is not legally required and is not implemented
widely), but instead used hospital reimbursement
as a surrogate parameter for these costs. How-
ever, the aim of the study was to calculate the
magnitude of the difference between costs and
revenues for patients with HA-MRSA-Is, and the
result was quite clear despite this approximation.
Although the 97.5 percentile was used as a
threshold value for a prolonged hospital stay,
this was not a case-control study and it is therefore
possible that factors other than the HA-MRSA-I
were responsible for a prolonged hospital stay.
Nevertheless, there is no doubt that hospital-
acquired infections are associated with a pro-
longed hospital stay [8,9,11] which is similar in
extent to the calculated excess to the threshold
value in the present study (mean 18.2 days).
The present cost analysis is the ﬁrst study to
use actual observations of reduced HA-MRSA-Is
instead of mathematical models of reduced
transmission and subsequent HA-MRSA-Is. The
screening programme was shown to be cost-
effective, even in a situation where MRSA was
endemic in the hospital. The low incidence rates
of positive MRSA patients at hospital admission,
together with the low number of cases of
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HA-MRSA-I that have to be prevented before
the screening programme becomes cost-effective,
indicates that a screening programme can be
recommended for most hospitals with an MRSA
problem, especially under the circumstances of
the prospective DRG payment system.
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